Supplementary Figure S1 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer

Key Points

• MAIN FINDING: CDK2/4/6 inhibitor PF-06873600 shows promising changes in tumor biomarkers among patients with breast cancer.
• KEY EVIDENCE: Data indicate significant changes from baseline in tumor biomarkers following both monotherapy and combination treatment.
• APPROACH: The study involved a phase I/IIa design assessing a first-in-class therapy in patients with breast cancer.
• SIGNIFICANCE: Findings may support further development of combination treatment strategies in breast cancer therapy.